Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | KMT2A fusion |
Therapy | CDKI-73 |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KMT2A fusion | acute myeloid leukemia | sensitive | CDKI-73 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, CDKI-73 treatment inhibited Cdk9 kinase activity and viability, and induced apoptosis in acute myeloid leukemia cell lines harboring KMT2A fusions in culture, and inhibited tumor growth and induced regression in a cell line xenograft model (PMID: 30194564). | 30194564 |
PubMed Id | Reference Title | Details |
---|---|---|
(30194564) | CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia. | Full reference... |